Ivim: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.ivimhealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “Ivim” on the pictured label, suggesting Ivim is the compounder of those drugs when in fact it is not. Accordingly, the representations on your website that Ivim is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA.”

2. 2

   “See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person's name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”)”

3. 3

   “Such steps may include: 1) Identifying the entities that produce the compounded products offered on your website; 2) Providing a representative sample of labeling for such products”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

ivimhealth.com returned a live storefront when we checked in August 2026, offering compounded GLP-1 programmes alongside branded Wegovy, Zepbound, Mounjaro and Ozempic, a membership discount scheme and a waitlist for peptide therapies.

Read this one differently from the rest of the roster. FDA did not say Ivim overstated what the medication does or misrepresented what it costs — it said the vial in the product photograph carries Ivim's name, and that a name on a drug label without qualification means the named company made it. Ivim, on FDA's account, did not. That matters to a price comparison in a way the marketing letters do not: when a branded vial arrives from a telehealth company, the brand on the label is the company you bought from, and the pharmacy that actually compounded the drug may not appear anywhere you can see. FDA's remedy makes the point plainly, since it asked the company to identify the entities that produce the products. If you are comparing two subscriptions on price, the label will not tell you whether you are comparing two different medicines or the same one twice.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Ivim failed to respond.